PT Kalbe Farma Tbk (PTKFY) AI Stock Analysis

• Market Cap: $4.01B
• Dividend Yield: 1.79%
• Average Volume (3M): 0.00
• Price to Earnings (P/E): 18.4
• Beta (1Y): 0.35
• Revenue Growth: 2.45%
• EPS Growth: 9.73%
• Country: US
• Employees: 12,841
• Sector: Healthcare
• Sector Strength: 43
• Industry: Drug Manufacturers - General
• EPS (TTM): 0.24
• Shares Outstanding: 234,066,960
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: <0.01
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: $18.00
• Price Target Upside: 4.11% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 72 Outperform
• Price Target: $20.00 ▲(15.67% Upside)

PT Kalbe Farma Tbk's strong financial performance, characterized by robust revenue growth and profitability, is the primary driver of its stock score. The technical analysis indicates a neutral trend, while the valuation suggests the stock is fairly priced. The absence of earnings call data and corporate events does not impact the score.

PT Kalbe Farma Tbk Business Overview & Revenue Model

Company Description

PT Kalbe Farma Tbk (PTKFY) is one of Indonesia's largest pharmaceutical companies, primarily engaged in the research, development, manufacturing, and marketing of a wide range of healthcare products. The company's operations are categorized into several sectors, including prescription pharmaceuticals, over-the-counter medications, nutritional products, and consumer health products. Kalbe Farma is known for its strong portfolio of products, which include prescription drugs, dietary supplements, and health food products aimed at improving the quality of life for consumers and addressing various health concerns.

How the Company Makes Money

PT Kalbe Farma Tbk generates revenue through multiple streams, primarily from the sale of its pharmaceutical products, which encompass prescription medications and over-the-counter drugs. The company's nutritional division also contributes significantly to its earnings by offering a variety of nutritional supplements and products designed for specific health needs. Additionally, Kalbe Farma operates in the consumer health segment, providing products that cater to everyday health and wellness. The company’s revenue is bolstered by strategic partnerships with healthcare providers, distribution networks, and collaborations with research institutions to enhance its product offerings. Moreover, Kalbe Farma's extensive distribution channels and marketing efforts help to expand its market reach, enabling the company to capture a larger share of the healthcare market and thereby increase its profitability.

PT Kalbe Farma Tbk Financial Statement Overview

Summary

PT Kalbe Farma Tbk demonstrates strong financial health with robust revenue growth and profitability. The company maintains a solid balance sheet with low leverage, enhancing financial stability. While cash flow metrics show some areas for improvement, particularly in Free Cash Flow Growth, the overall financial position remains strong, supporting continued growth and operational efficiency.

Income Statement

PT Kalbe Farma Tbk exhibits strong income statement metrics with a consistent increase in revenue and profitability. The TTM Gross Profit Margin is healthy at 40.18%, and the Net Profit Margin is solid at 10.22%. The company has shown impressive revenue growth of 81.2% in the TTM period, indicating robust business expansion. EBIT and EBITDA margins are also strong, reflecting efficient operational management.

Balance Sheet

The balance sheet of PT Kalbe Farma Tbk is stable with a low Debt-to-Equity Ratio of 0.0348, indicating low leverage and financial risk. The Return on Equity (ROE) is commendable at 15.01%, showcasing effective use of equity capital. The Equity Ratio is strong, suggesting a solid capital structure. However, the slight decrease in Stockholders' Equity over the periods could be a point to monitor.

Cash Flow

Cash flow analysis reveals a mixed picture. The Free Cash Flow Growth Rate is negative at -20.9% in the TTM, which could be a concern. However, the Operating Cash Flow to Net Income Ratio is healthy at 0.799, indicating good cash generation relative to net income. The Free Cash Flow to Net Income Ratio is also strong at 0.787, reflecting efficient cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	33.38T	32.63T	30.45T	28.93T	26.26T	23.11T
Gross Profit	13.52T	12.96T	11.82T	11.70T	11.28T	10.25T
EBITDA	4.87T	4.61T	4.02T	5.25T	4.87T	4.35T
Net Income	3.41T	3.24T	2.77T	3.38T	3.18T	2.73T
Balance Sheet
Total Assets	29.51T	29.43T	27.06T	27.24T	25.67T	22.56T
Cash, Cash Equivalents and Short-Term Investments	3.95T	4.87T	3.40T	4.10T	6.48T	5.40T
Total Debt	779.98B	559.22B	618.54B	1.17T	626.16B	1.16T
Total Liabilities	5.32T	4.84T	3.94T	5.14T	4.40T	4.29T
Stockholders Equity	22.40T	22.79T	21.42T	20.39T	19.58T	17.41T
Cash Flow
Free Cash Flow	2.87T	3.53T	1.73T	2.90T	1.83T	3.10T
Operating Cash Flow	3.71T	4.79T	2.91T	3.77T	2.83T	4.21T
Investing Cash Flow	-439.87B	-1.25T	-1.14T	-1.37T	-1.06T	-951.22B
Financing Cash Flow	-3.15T	-2.09T	-2.44T	-2.41T	-745.18B	-1.10T

PT Kalbe Farma Tbk Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 17.29
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTKFY, the sentiment is Positive. The current price of 17.29 is below the 20-day moving average (MA) of 17.67, below the 50-day MA of 18.39, and above the 200-day MA of 16.63, indicating a neutral trend. The MACD of -0.34 indicates Negative momentum. The RSI at 51.16 is Neutral, neither overbought nor oversold. The STOCH value of 69.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PTKFY.

PT Kalbe Farma Tbk Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PTKFY	72 Outperform	$4.01B	18.37	15.61%	1.79%	2.45%	9.73%
GRFS	71 Outperform	$8.84B	22.19	5.41%	1.33%	10.05%	98.22%
Sector *	51 Neutral	$7.44B	-0.20	-46.00%	2.27%	22.80%	-2.27%
OGN	50 Neutral	$2.44B	3.49	159.64%	6.39%	-1.02%	-30.57%